Japanese pharmaceutical company with a focus on neuroscience and oncology, known for developing the Alzheimer's treatment Leqembi (lecanemab) in partnership with Biogen.
Eisai is expanding its UK packaging and manufacturing footprint for Leqembi with a £65M government-backed investment, securing capacity for the Alzheimer's antibody as global demand ramps post-FDA approval.